Overview
Peptides are not illegal as a class in Belgium, but most popular research/compounding peptides (BPC-157, TB-500, ipamorelin, etc.) have no marketing authorisation and therefore cannot be legally sold or administered as medicines for human use. The Federal Agency for Medicines and Health Products (FAMHP/AFMPS/FAGG) regulates medicines under the Law of 25 March 1964 and the Royal Decree of 14 December 2006; a product only counts as a regulated 'medicine' if it is presented or used to treat/prevent disease or alter physiological function in humans, so peptides marketed strictly as 'research chemicals not for human use' fall outside that definition, occupying a gray zone rather than being explicitly banned. By contrast, approved peptide medicines like semaglutide (Ozempic/Wegovy) are prescription-only and have been subject to Belgian government supply restrictions, and doping-relevant peptides (growth-hormone secretagogues, TB-500, BPC-157) are separately banned in competitive sport by WADA rules that Belgian anti-doping bodies enforce.
Key Points
- Belgium's FAMHP defines a 'medicine' under the Law of 25 March 1964 as any substance claiming to cure or prevent disease or to alter physiological function in humans, and only substances meeting that definition (and holding a marketing authorisation) can be legally sold as drugs. [1]
- Research peptides such as BPC-157, GHK-Cu, and retatrutide sold in Belgium strictly for in-vitro/laboratory research are not classified as 'medicines' under the 1964 Law and 2006 Royal Decree and are not on FAMHP's lists of controlled narcotics or hormones requiring prior authorisation, but that status does not make them a freely sellable consumer product for human use. [2]
- A person cannot personally import prescription-only or non-EU-authorised medicines into Belgium themselves; the FAMHP states that import for personal therapeutic use must always be carried out by a Belgian pharmacist, based on a doctor's prescription and physician's statement of medical necessity. [7]
- Under Article 3 of Belgium's 1964 Medicines Act, personal import of an otherwise-unavailable medicine is only permitted where it is medically necessary, no suitable alternative exists on the Belgian market, and a licensed physician has prescribed it. [9]
- Belgium's FAMHP and health minister imposed a Royal Decree restricting the GLP-1 medicine Ozempic (semaglutide) to diabetic patients and severely obese patients (BMI 35+, or 30+ with comorbidities), explicitly banning its use purely for weight loss outside those categories during the 2023-2024 shortage. [5]
- Sciensano, Belgium's national public health institute, has documented that falsified/counterfeit peptide drugs sold online as 'research chemicals' and seized by Belgian customs and regulators between 2009 and 2017 frequently contained toxic impurities such as arsenic and lead. [3]
- Failing to hold a valid manufacturing or distribution authorisation for medicines in Belgium, or otherwise violating the 1964 Medicines Act's authorisation requirements, can constitute a criminal offence with penalties defined in that law. [11]
- Growth-hormone releasing peptides, growth-hormone secretagogues, and healing/repair peptides like TB-500 are listed under WADA's S2 category as prohibited substances in organized sport, a framework Belgian anti-doping authorities apply to competitive athletes even though this doping rule is separate from general consumer drug law. [12]